Edition:
United Kingdom

Lannett Company Inc (LCI.N)

LCI.N on New York Stock Exchange

5.08USD
13 Dec 2018
Change (% chg)

$-0.19 (-3.61%)
Prev Close
$5.27
Open
$5.28
Day's High
$5.28
Day's Low
$5.02
Volume
282,209
Avg. Vol
353,248
52-wk High
$30.35
52-wk Low
$3.34

Latest Key Developments (Source: Significant Developments)

Lannett Announces Amendment To Credit Agreement
Tuesday, 11 Dec 2018 

Dec 11 (Reuters) - Lannett Company Inc ::LANNETT ANNOUNCES AMENDMENT TO CREDIT AGREEMENT.LANNETT COMPANY INC - COMPANY EXPECTS TO BE WELL WITHIN ITS FINANCIAL COVENANTS THROUGH MATURITY DATE OF TERM A LOANS.LANNETT COMPANY INC - IN EXCHANGE, COMPANY AGREED TO INCLUDE A MINIMUM LIQUIDITY COVENANT OF $75 MILLION.LANNETT - AMENDMENT RAISES REQUIRED SECURED NET LEVERAGE RATIO APPLICABLE TO FINANCIAL LEVERAGE RATIO COVENANT FROM 3.25 TO 4.25 TIMES AS OF DEC 31.LANNETT COMPANY INC - CURRENTLY, REQUIRED SECURED NET LEVERAGE RATIO STANDS AT 3.75 TIMES..LANNETT COMPANY INC - IN EXCHANGE, COMPANY AGREED TO A 25 BASIS POINT INCREASE TO INTEREST RATE MARGIN PAID ON TERM A LOANS.LANNETT COMPANY INC - ENTERED INTO AN AMENDMENT OF ITS CREDIT AGREEMENT EFFECTING TERM A LOANS.  Full Article

Lannett Announces Amendment To Credit Agreement
Tuesday, 11 Dec 2018 

Dec 11 (Reuters) - Lannett Company Inc ::AMENDMENT RAISES REQUIRED SECURED NET LEVERAGE RATIO APPLICABLE TO FINANCIAL LEVERAGE RATIO COVENANT FROM 3.25 TO 4.25 TIMES AS OF DEC 31, 2019.LANNETT ANNOUNCES AMENDMENT TO CREDIT AGREEMENT.COMPANY EXPECTS TO BE WELL WITHIN ITS FINANCIAL COVENANTS THROUGH MATURITY DATE OF TERM A LOANS.IN EXCHANGE, COMPANY AGREED TO INCLUDE A MINIMUM LIQUIDITY COVENANT OF $75 MILLION.CURRENTLY, REQUIRED SECURED NET LEVERAGE RATIO STANDS AT 3.75 TIMES..IN EXCHANGE, COMPANY AGREED TO A 25 BASIS POINT INCREASE TO INTEREST RATE MARGIN PAID ON TERM A LOANS.ENTERED INTO AN AMENDMENT OF ITS CREDIT AGREEMENT EFFECTING TERM A LOANS.  Full Article

Amneal Completes Transition Agreement With Amneal To Begin Selling Levothyroxine
Monday, 12 Nov 2018 

Nov 12 (Reuters) - Amneal Pharmaceuticals Inc ::AMNEAL COMPLETES TRANSITION AGREEMENT WITH LANNETT COMPANY TO BEGIN COMMERCIALIZATION OF LEVOTHYROXINE ON DECEMBER 1ST.AMNEAL PHARMACEUTICALS INC - AGREEMENT ACCELERATES AMNEAL'S TIME TO MARKET WITH HIGH VALUE GENERIC.AMNEAL PHARMACEUTICALS - AMNEAL DOES NOT EXPECT TRANSACTION TO HAVE A MATERIAL IMPACT ON ITS FULL YEAR 2018 RESULTS.  Full Article

Lannett Enters Into Agreement With Amneal Pharmaceuticals For Levothyroxine
Monday, 12 Nov 2018 

Nov 12 (Reuters) - Lannett Company Inc ::LANNETT ENTERS INTO AGREEMENT WITH AMNEAL PHARMACEUTICALS FOR LEVOTHYROXINE.LANNETT COMPANY INC - LANNETT LOCKS IN $50 MILLION OF GROSS PROFIT FOR 16-WEEK PERIOD.LANNETT COMPANY INC - LANNETT WILL RECEIVE AN UPFRONT PAYMENT OF $50 MILLION, OTHER TERMS OF TRANSACTION WERE NOT DISCLOSED.LANNETT COMPANY INC - AGREEMENT ALLOWS LANNETT TO CONTINUE TO RECOGNIZE REVENUE AND EBITDA FOR REMAINDER OF JSP CONTRACT TERM.LANNETT - AMNEAL TO BE CO'S SOLE CUSTOMER FOR LEVOTHYROXINE SODIUM BEGINNING DECEMBER 1, 2018 THROUGH MARCH 23, 2019.  Full Article

Lannett Company Approves Plan In Sept 2018 To Sell Active Pharmaceutical Ingredient Manufacturing, Distribution Business Of Cody Laboratories Unit
Friday, 26 Oct 2018 

Oct 26 (Reuters) - Lannett Company Inc ::LANNETT COMPANY - APPROVED PLAN IN SEPT 2018 TO SELL ACTIVE PHARMACEUTICAL INGREDIENT MANUFACTURING, DISTRIBUTION BUSINESS OF CODY LABORATORIES UNIT.EXCLUDED FROM SALE PLAN APPROVED IN SEPT WILL BE MANUFACTURING OF FINISHED DOSAGE FORM OF CO'S COCAINE HYDROCHLORIDE PRODUCT LINE.AS RESULT OF FAIR VALUE ANALYSIS OF CODY API BUSINESS, CO DETERMINED IMPAIRMENT OF ASSETS HELD FOR SALE OF $27 MILLION - $33 MILLION.IMPAIRMENT WILL RESULT IN A NONCASH CHARGE TO Q1 EARNINGS, HAS NO IMPACT ON CO'S FINANCIAL COVENANT LEVERAGE RATIO - SEC FILING.  Full Article

Lannett And Adare Enter Into Distribution Agreement For Dexmethylphenidate Hydrochloride Extended Release Capsules
Monday, 22 Oct 2018 

Oct 22 (Reuters) - Lannett Company Inc ::LANNETT AND ADARE ENTER INTO DISTRIBUTION AGREEMENT FOR DEXMETHYLPHENIDATE HYDROCHLORIDE EXTENDED RELEASE CAPSULES.LANNETT - WILL PRIMARILY PROVIDE SALES, MARKETING AND DISTRIBUTION SUPPORT FOR PRODUCT, FOR WHICH IT WILL RECEIVE A PERCENTAGE OF NET PROFITS.LANNETT COMPANY INC - LANNETT EXPECTS TO COMMENCE MARKETING WITHIN A FEW MONTHS..LANNETT COMPANY INC - OTHER FINANCIAL TERMS WERE NOT DISCLOSED..  Full Article

Lannett Says Nonrenewal Of Deal With JSP Represents A “Triggering Event” Under U.S. GAAP
Thursday, 23 Aug 2018 

Aug 23 (Reuters) - Lannett Company Inc ::LANNETT SAYS DETERMINED NONRENEWAL OF DEAL WITH JEROME STEVENS PHARMACEUTICALS REPRESENTS A “TRIGGERING EVENT” UNDER U.S. GAAP - SEC FILING.LANNETT COMPANY - BELIEVES THAT ITS IMPAIRMENT ASSESSMENT TO LIKELY RESULT IN MATERIAL IMPAIRMENT OF THE CO'S GOODWILL.LANNETT COMPANY INC - ANY IMPAIRMENT WOULD RESULT IN NONCASH CHARGE TO EARNINGS IN Q1 OF FISCAL 2019.LANNETT SAYS DUE TO "TRIGGERING EVENT", TO PERFORM ANALYSIS TO DETERMINE POTENTIAL FOR IMPAIRMENT OF GOODWILL, CERTAIN LONG-LIVED ASSETS IN Q1 2019.  Full Article

Lannett Co Sees FY 2018 Adjusted EPS $3.08 To $3.10
Monday, 20 Aug 2018 

Aug 20 (Reuters) - Lannett Company Inc ::LANNETT PROVIDES UPDATE ON CONTRACT RENEWAL WITH JEROME STEVENS PHARMACEUTICALS.SEES FY 2018 ADJUSTED EARNINGS PER SHARE $3.08 TO $3.10.SEES Q4 2018 ADJUSTED EARNINGS PER SHARE $0.62 TO $0.64.SEES FY 2018 GAAP EARNINGS PER SHARE $0.73 TO $0.75.SEES Q4 2018 GAAP LOSS PER SHARE $0.30 TO $0.32.SEES FY 2019 SALES $50 MILLION.SEES FY 2018 SALES ABOUT $685 MILLION.SEES Q4 2018 SALES ABOUT $171 MILLION.FOR FISCAL 2018 Q4, NET SALES ARE EXPECTED TO BE APPROXIMATELY $171 MILLION.LANNETT COMPANY - DISTRIBUTION AGREEMENT WITH JEROME STEVENS PHARMACEUTICALS, WHICH EXPIRES ON MARCH 23, 2019, WILL NOT BE RENEWED.FOR FISCAL 2018 Q4 GAAP LOSS PER SHARE ATTRIBUTABLE TO LANNETT TO BE BETWEEN $0.30 AND $0.32.SEESS FISCAL 2018 Q4 ADJUSTED EPS ATTRIBUTABLE TO LANNETT TO BE BETWEEN $0.62 AND $0.64.EXPECT TO EXPAND RESTRUCTURING INITIATIVES TO FURTHER REDUCE EXPENDITURES.Q4 EARNINGS PER SHARE VIEW $0.66, REVENUE VIEW $173.5 MILLION -- THOMSON REUTERS I/B/E/S.FY2018 EARNINGS PER SHARE VIEW $3.12, REVENUE VIEW $687.2 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Lannett Company Expects To Report Impairment Charge Of About $21.5 Mln
Monday, 6 Aug 2018 

Aug 6 (Reuters) - Lannett Company Inc ::LANNETT COMPANY - CONCLUDED EXPECTS TO REPORT IMPAIRMENT CHARGE OF ABOUT $21.5 MILLION.LANNETT COMPANY INC - ALSO CONCLUDED EXPECTS TO REPORT AN IMPAIRMENT CHARGE OF APPROXIMATELY $3.5 MILLION.LANNETT - CHARGE OF ABOUT $21.5 MILLION RELATED TO FACILITY, OTHER PLANT-RELATED ASSETS ASSOCIATED TO EXPANSION PROJECT AT CODY LABORATORIES.LANNETT COMPANY - IMPAIRMENT CHARGES WILL BE REPORTED IN CO'S RESULTS OF OPERATIONS FOR THREE MONTHS AND YEAR ENDED JUNE 30, 2018 - SEC FILING.  Full Article

Lannett Enters Licensing Agreement For Generic Concerta, Methylphenidate Hydrochloride ER Tablets
Friday, 3 Aug 2018 

Aug 3 (Reuters) - Lannett Company Inc ::LANNETT ENTERS LICENSING AGREEMENT FOR GENERIC CONCERTA®, METHYLPHENIDATE HYDROCHLORIDE ER TABLETS.LANNETT COMPANY INC - UNDER AGREEMENT, CO WILL PRIMARILY PROVIDE SALES, MARKETING AND DISTRIBUTION SUPPORT OF ANDOR'S METHYLPHENIDATE ER PRODUCT.LANNETT COMPANY INC - ENTERED INTO AN EXCLUSIVE PERPETUAL LICENSING AGREEMENT WITH ANDOR PHARMACEUTICALS, LLC.LANNETT - BASED ON ANDOR'S TARGET ACTION DATE, "OPTIMISTIC" ABOUT LAUNCHING PRODUCT WELL WITHIN CALENDAR 2019.LANNETT - WILL GET PERCENT OF NET PROFITS FOR PROVIDING SALES, MARKETING AND DISTRIBUTION SUPPORT OF ANDOR'S METHYLPHENIDATE ER PRODUCT.LANNETT CO - ANDOR'S PENDING ANDA OF METHYLPHENIDATE EXPECTED TO BE APPROVED AS AN AB-RATED GENERIC EQUIVALENT TO BRAND CONCERTA.  Full Article